Comparative Pharmacology
Head-to-head clinical analysis: METOZOLV ODT versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOZOLV ODT versus PROMETHAZINE DM.
METOZOLV ODT vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic